[ANMCO Expert opinion: Bempedoic acid place in therapy for hypercholesterolemia management]

Growing evidence supporting the central role of hypercholesterolemia in atherosclerotic disease pathogenesis and progression has led to the development of new therapeutic approaches. Bempedoic acid has recently been approved for marketing following several studies that demonstrated its efficacy and safety. This drug represents a new therapeutic option that, like statins, acts on the enzymatic cascade that is involved in cholesterol synthesis. However, its hepatic selectivity of action reduces the risk of muscle adverse effects. This ANMCO document highlights clinical settings in which bempedoic acid represents a particularly useful therapeutic option. Furthermore, the document discusses the possibilities of use based on both international recommendations and current national regulations. Finally, we report practical guidance on hypercholesterolemia management in light of the available therapeutic armamentarium.

 

Comments:

The growing evidence supporting the central role of hypercholesterolemia in the pathogenesis and progression of atherosclerotic disease has led to the development of new therapeutic approaches. One such approach is the use of bempedoic acid, which has recently been approved for marketing after demonstrating efficacy and safety in several studies.

Bempedoic acid is similar to statins in that it acts on the enzymatic cascade involved in cholesterol synthesis. However, its hepatic selectivity of action reduces the risk of muscle adverse effects commonly associated with statin use. This makes bempedoic acid a particularly useful therapeutic option in certain clinical settings.

An ANMCO document highlights these clinical settings where bempedoic acid can be beneficial. It also discusses the possibilities of its use based on international recommendations and current national regulations. This document provides practical guidance on managing hypercholesterolemia, taking into account the available therapeutic options.

The specific details of the clinical settings, international recommendations, and national regulations discussed in the ANMCO document are not provided in the given text. However, it emphasizes that bempedoic acid represents a valuable therapeutic option for managing hypercholesterolemia, especially in cases where muscle adverse effects are a concern.

It is important to note that the information provided here is a summary based on the given text and does not replace the complete ANMCO document or personalized medical advice. For detailed and specific guidance on hypercholesterolemia management and the use of bempedoic acid, it is recommended to consult the ANMCO document or consult with a healthcare professional.

Related Products

Cat.No.	Product Name	Information
S7953	Bempedoic acid (ETC-1002)	Bempedoic acid (ETC-1002),also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).

Related Targets

ATP-citrate lyase LDL AMPK